Aviado · Research
Longevity Daily
Friday, May 29, 2026
Listen
Today's Brief
Today's strongest stories converge on a sharpening science of biological aging — and some important course corrections. A landmark cross-species aging clock published in Nature, our must-read, brings us closer to identifying which interventions actually move the needle on human lifespan. The Phase 3 failure of semaglutide in Alzheimer's and emerging safety questions around long-term NMN use both serve as evidence-check reminders that promising signals don't always pan out. Rounding out the issue: the newly cracked mechanism behind metformin's benefits and a comprehensive review of every intervention proven to lower biological age.
10 stories6 peer-reviewed2 trials
Cognitive Health & Neuroprotection
'Universal' Aging Clocks Identify the Biological Markers That Predict Longevity Across Species
A new study published in Nature has developed aging clocks that work across multiple species, identifying shared molecular patterns that predict lifespan with remarkable precision. Researchers say the clocks could serve as a universal benchmark for testing which longevity drugs and supplements actually slow biological aging in humans — a tool the field has long lacked. This matters because most aging intervention research has lacked cross-validated measures of whether something actually works; these clocks could change that. The findings reinforce what health-optimization enthusiasts already know: biological age, not your birthdate, is the number that matters most for healthspan.
Read more →Semaglutide's Phase 3 Alzheimer's Trial Failed — Here's What That Means for GLP-1 Optimism
Despite observational data showing 40–70% lower Alzheimer's risk in patients taking semaglutide versus other diabetes drugs, the Phase 3 EVOKE trial found no significant cognitive benefit in Alzheimer's patients. The trial had robust design — long treatment duration, biomarker-rich endpoints including MRI and CSF markers — making this a clean negative, not a methodological failure. For those hoping GLP-1s might double as cognitive protection, this is a meaningful recalibration: strong real-world associations don't always survive randomized testing.
Read more →Aged Immune Cells Secrete a Protein That Degrades the Brain — and the Effect Is Reversible
Researchers have identified Granzyme K, a protein secreted by aging T cells, as a significant driver of cognitive decline — and found that blocking its activity reversed the effect in animal models. This adds to growing evidence that the immune system's aging trajectory is directly linked to brain health, not just infection resistance. The reversibility angle is particularly significant: if Granzyme K-targeted therapies advance to humans, they could offer a non-brain-direct approach to preserving cognition in later life.
Read more →Supplements & Compounds
New Lab Research Raises Kidney Safety Questions About Long-Term NMN Use in Older Adults
Laboratory research highlighted by ConsumerLab suggests that long-term NMN supplementation might cause kidney injury in older adults — a meaningful caution given the widespread use of NMN as a NAD+ booster. The finding is pre-clinical, not a human trial, so the real-world risk magnitude remains unclear. Still, given the relative lack of long-term human safety data on NMN, those over 60 taking it daily should flag this with their physician.
Read more →Novel Herring-Oil Supplement Cuts LDL Cholesterol 7% in Eight-Week Randomized Trial
A University of Bergen randomized clinical trial found that cetoleic acid (CECO), an omega-9/omega-11 fatty acid derived from herring oil, reduced LDL cholesterol by 7% over eight weeks in overweight and obese adults. Published in the British Journal of Nutrition, this is the first clean clinical evidence for cardiovascular benefits from this largely unfamiliar lipid compound. Early data from a single trial, but the RCT design is solid — cetoleic acid is a supplement category worth watching.
Read more →Research & Papers
A Comprehensive Review Maps Every Intervention Proven to Lower Your Biological Age
A new Frontiers in Genetics review catalogs the full range of interventions shown to reduce biological age on next-generation epigenetic clocks — covering exercise, caloric restriction, metformin, rapamycin, NMN, and combined drug protocols. A notable finding from one small trial: combining growth hormone, DHEA, and metformin reduced both DNAm PhenoAge and GrimAge over 12 months in nine healthy men (Fahy et al., 2019). Most evidence is still from small studies, but this is the most actionable roadmap yet for health-optimizers wanting to know which levers actually move biological age.
Read more →Scientists Finally Crack the Molecular Mechanism Behind Metformin's Longevity Benefits
Researchers at Université de Montréal have identified exactly how metformin works at the cellular level — resolving a long-standing mystery about one of the most studied potential longevity drugs. Understanding the mechanism could clarify who benefits most and open the door to more targeted compounds with better efficacy and fewer side effects. For the millions already taking metformin off-label for anti-aging purposes, this is the mechanistic foundation the field has been waiting for.
Read more →Israeli Scientists Use Sirt6 to 'Rewind' Aging in Mouse Livers
Researchers in Israel have shown that boosting the protein Sirt6 reverses aging-related damage in mouse liver tissue, with longevity researcher Nir Barzilai calling it evidence for the possibility of improving healthspan. This is a mouse study and clinical translation remains years away — but Sirt6 is one of the most consistently validated longevity targets in geroscience. As Sirt6 activators move toward human testing, this adds important mechanistic weight to the case.
Read more →A Single Gene Therapy Injection Could Control Cholesterol for Life
An experimental gene therapy in development may eliminate the need for daily statins or periodic PCSK9 injections with a single treatment, permanently lowering LDL cholesterol by targeting a well-validated cardiovascular pathway. The therapy is still in early-stage testing and will require substantial further study before human use. But if it holds in larger trials, this would represent one of the most consequential cardiovascular longevity advances in decades.
Read more →Industry & Policy
Wearables Enter the Scientific Mainstream as WHOOP Joins Federal Longevity Research Program
Longevity.Technology examines the growing role of consumer wearables in aging science, spotlighting WHOOP's participation in ARPA-H's federally funded Prospr program — designed to identify biomarkers and assessment tools for age-related disease. The piece surfaces the industry's central tension: wearables generate rich longitudinal health data, but accuracy concerns, privacy risks, and overhyped consumer claims remain unresolved. As wearable data moves from consumer gadget to clinical currency, the regulatory and scientific stakes are rising fast.
Read more →